A total of @ patients with metastatic clear cell renal cell carcinoma were randomly assigned equally to arm A ( bevacizumab monotherapy @ mg/kg intravenously -LSB- IV -RSB- every @ weeks ) , B ( bevacizumab @ mg/kg IV every @ weeks and temsirolimus @ mg IV every week ) , C ( bevacizumab @ mg/kg IV every @ weeks and sorafenib @ mg orally twice daily on days @ to @ , @ to @ , @ to @ , and @ to @ ) , or D ( sorafenib @ mg twice daily and temsirolimus @ mg IV weekly ) .